Back to Top Skip to main content Skip to sub-navigation

Hepburn: DOD role in Operation Warp Speed was ‘transformative’

Image of Medical technician getting a syringe ready to give a vaccine. Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center Fort Sam Houston, Texas, November 16, 2020. BAMC is one of five Defense Health Agency military medical treatment facilities participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics. (Photo by Jason Edwards, Brooke Army Medical Center.)

Recommended Content:

COVID-19 Vaccine Efforts | Vaccine Trials | Coronavirus | Coronavirus and the COVID-19 Vaccine

The director of the Department of Defense’s Operation Warp Speed told The Society of Federal Health Professionals that he is 'incredibly proud’ of the work his team has done with the Department of Health and Human Services in finding a vaccine for COVID-19. Dr. Matthew Hepburn’s praise for DOD came during a speech to the AMSUS virtual annual meeting Dec. 8.

The DOD’s role in Operations Warp Speed (OWS) was “transformative,” said Hepburn, OWS development lead, pointing to operational planning, logistics and supply chains, which “is in our DNA” at DOD. “It comes very naturally because that is what we do…and that has made all the difference,” he told the audience of more than 1,500 online attendees.

For example, he said DOD’s expertise in obtaining contracts quickly resulted in OWS getting “a really good deal in record time that was mutually beneficial” to the six vaccine manufacturers the joint operation decided to pursue for an approved vaccine for COVID-19. Those manufacturers are Pfizer, Moderna, AstraZeneca, Janssen, Novavax, and Sanofi.

“The Department of Defense’s unique contracting experience … and other transactions have allowed us to come from where we think are the right contacts to having long-term contracts,” Hepburn said.

Pfizer and Moderna have applied for emergency use authorization from the Food and Drug Administration. Pfizer’s application will be reviewed by an FDA advisory committee of vaccine experts Dec. 10, and Moderna’s application will be reviewed a week later. The FDA usually, but not always, accepts its advisory panels’ recommendations.

The FDA announced on Dec. 8 that its review of the Pfizer vaccine found it to be safe and efficacious, meeting the requirements for emergency use authorization. The vaccine showed a strong protective effect after the first of two doses, according to the FDA.

The OWS’ chief operating officer, Army Gen. Gustave Perna, “has been very clear that we will have trucks rolling within 24 hours of approval of the first vaccine,” Hepburn said.

Once the vaccine is first available to frontline health care workers and elderly care facilities, “we need you to tell our communities that this is just one layer of a multi-level strategy” to protect against COVID-19, he stated.

He urged the health care community “to convey a message that these vaccines are safe and efficacious, and that vaccination is important” as a counterpoint to widespread misinformation in the general public about vaccines and the need for vaccination against the disease.

Clinical trials for the candidate vaccines are ongoing and represent the diversity of the general population, Hepburn said, and were done “in anticipation of trying to increase confidence” among the public. For example, at least 25% of clinical trial participants are over the age of 65, a population not normally used for clinical trials but one at greater risk from COVID-19, he noted.

The number of doses needed for immunizations is “really a moving target, which is not necessarily a bad thing,” Hepburn said. “The consistency and cadence of manufacturing improves over time, and more doses are available than we thought would be available last week.”

OWS’ project team asks for “more doses on a daily basis,” he noted.

Armed services research efforts prior to the pandemic will allow for future innovation and speed of vaccine and therapeutics development, Hepburn said.

“If we hadn’t made those investments 10 years ago, there is no way we could have achieved the speed” of going from research and development, to candidates, to clinical trials, to approval and distribution, he said.

He noted that the DOD’s “clinical research enterprise led us to be involved in the enrollment right now in the AstraZeneca clinical trials.”

He called the department’s research enterprise “an incredibly powerful tool to confront 21st century threats,” and that “this is the new standard for rapid product development, and will apply not only to pandemics but also to develop product for combat health in half the time. Imagine how fast we could go in force protection” using the new paradigm, he said.

During a question and answer session, Hepburn emphasized that the AMSUS audience “needs to remind people at the DOD and in the community at large how well DOD can work” when confronted by new viral or other national security and health care threats.

“One of the most important lessons learned is the value of military leadership” in overcoming obstacles at a rapid clip, he said, noting the DOD “didn’t take over a public health initiative, but collaborated on a project that involved not only what we’re doing for the American people but also globally.”

You also may be interested in...

Communication to ABA Providers Regarding Continued Temporary Authorization to Utilize Telehealth for CPT Code 97156 During the COVID-19 National Emergency

Publication
6/3/2020

TRICARE is announcing the continuation of the temporary exception to policy regarding the use of synchronous telehealth (TH) capabilities (both audio and video) for Applied Behavior Analysis (ABA) Family Adaptive Behavior Treatment Guidance services specifically during this COVID-19 pandemic.

Recommended Content:

Coronavirus | About TRICARE

Force Health Protection Guidance (Supplement 9) -Department of Defense Guidance for Deployment and Redeployment of Individuals and Units during the Novel Coronavirus Disease 2019 Pandemic

Publication
5/26/2020

This memorandum provides force health protection (FHP) deployment and redeployment guidance for Service members (including Reserve Component (RC) and National Guard members in a title 10 or title 32 duty status) and DoD civilian employees deploying within and outside the United States during the COVID-19 pandemic, consistent with references (a) and (b).

Recommended Content:

Coronavirus

Guidance for Commanders on Risk-Based Changing of Health Protection Condition Levels During the Coronavirus Disease 2019 Pandemic

Publication
5/20/2020

This memorandum provides guidance for commanders to consider when making decisions to change health protection condition (HPCON) levels as COVID-19 pandemic conditions on and adjacent to our installations begin to improve.

Recommended Content:

Coronavirus

Resuming Elective Surgical, Invasive, and Dental Procedures in Military Medical and Dental Treatment Facilities

Publication
5/19/2020

This memorandum provides guidance on how each Military Medical Treatment Facility (MTF) and Dental Treatment Facility (DTF) may resume elective medical and dental procedures.

Recommended Content:

Public Health | Coronavirus

Modification and Reissuance of DoD Response to Coronavirus Disease 2019 -Travel Restrictions

Publication
4/20/2020

All DoD Service members will stop movement, both internationally and domestically, while this memorandum is in effect. All DoD civilian personnel, and dependents of DoD Service members and DoD civilian personnel, whose travel is Government-funded will stop movement, both internationally and domestically, while this memorandum is in effect.

Recommended Content:

Coronavirus

Implementation Guidance for Presidential Memorandum, "Providing Federal Support for Governor's Use of the National Guard to Respond to COVID-19 ," Dated April 7, 2020

Publication
4/14/2020

Recommended Content:

Coronavirus

Benefits Eligibility for 32 USC 502(f) Missions

Publication
4/14/2020

A chart outlining the various Benefits Eligibility for 32 USC 502(f) Missions

Recommended Content:

Coronavirus | About TRICARE

Memorandum on Providing Federal Support for Governors' Use of the National Guard to Respond to COVID-19

Publication
4/14/2020

Recommended Content:

Coronavirus

Delegation of Authority for Reserve Component Activation Authorities during the Coronavirus Disease 2019 Response

Publication
4/10/2020

This delegation assigns to the Service Secretaries the authority to activate Reserve Component personnel and to modify their orders as needed to employ and retain them for the COVID-19 response.

Recommended Content:

Coronavirus

Authorization to Employ Military Medical Capabilities to Treat COVID-19 Patients

Publication
4/8/2020

Effective immediately, the Commander, U.S Northern Command, is authorized, as he deems necessary and appropriate, to employ military medical capabilities under his operational control to treat patients who have contracted coronavirus disease 2019 (COVID-19).

Recommended Content:

Coronavirus

Decision Memorandum on TRICARE Implementation of the "Families First Coronavirus Response Act"

Publication
4/7/2020

The Families First Coronavirus Response Act, Public Law 116-127, Division F, Section 6006(a), limits TRICARE authority to impose copayment or other cost-sharing for novel coronavirus (COVID-19) testing and related provider visits that result in orders for or administration of Food and Drug Administration (FDA) approved, cleared, or authorized diagnostic products. In order for the Defense Health Agency (DHA) to implement, the Assistant Secretary of Defense for Health Affairs (ASD(HA)) must acknowledge the self-executing authority of the statute and direct the Director, DHA, or designee, to issue guidance implementing the statutory provisions.

Recommended Content:

About TRICARE | Coronavirus

DoD Guidance on the Use of Cloth Face Coverings

Publication
4/5/2020

Effective immediately, to the extent practical, all individuals on DoD property, installations, and facilities will wear cloth face coverings when they cannot maintain six feet of social distance in public areas or work centers (this does not include in a Service member's or Service family member's personal residence on a military installation).

Recommended Content:

Coronavirus | Public Health

Policy on Accessions and Accessions Training during the COVID-19 Outbreak

Publication
4/3/2020

The Military Departments must seek ways to maximize accessions in a responsible manner to minimize a reduction in military end strength and the potential deterioration of mid-and long-term readiness and capacity.

Recommended Content:

Coronavirus

Transition of Military Medical Treatment Facilities from Military Departments to the Defense Health Agency during the COVID-19 Response

Publication
4/2/2020

The Department's MTF transition plan is conditions-based. While the transition of MTFs to DHA is continuing, the COVID-19 response requirements are impacting DHA's ability to meet all required conditions. The need for the DHA and MILDEPs to refocus efforts away from the transition to support the COVID-19 response led to questions regarding the future of MTF Transition.

Recommended Content:

Coronavirus | Military Health System Transformation

Tiered Telehealth Health Care Support for COVID-19

Publication
3/31/2020

This memorandum establishes guidance for the use of Telehealth (TH) Information Technology (IT) tools in support of the clinical care required for patients across the spectrum of COVID-19 illness

Recommended Content:

About TRICARE | Public Health | Coronavirus
<< < 1 2 3 4 5 > >> 
Showing results 46 - 60 Page 4 of 5
Refine your search
Last Updated: September 01, 2021

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.